Navigation Links
Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Date:3/1/2011

s proprietary endothelial cell-based platform to prevent solid tumor growth, cancer recurrence and metastatic disease.

About Pervasis Pervasis Therapeutics, Inc. is a clinical stage company that is developing groundbreaking endothelial cell-based therapies designed to regulate the body's natural healing and repair processes in various critical therapeutic areas. The company has initially focused on developing therapies to improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stent placements, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs. The company's lead program, Vascugel®, has demonstrated proof of concept and safety in two Phase 2 clinical trials. Pervasis is also applying its endothelial cell-based platform technology to develop an oncology therapy focused on preventing solid tumor growth, cancer recurrence and metastatic disease, as well as products for inflammatory disease and orthopedic injury.

Pervasis is a privately held company with funding from Flagship Ventures, Polaris Venture Partners, Highland Capital Partners and the Richter Family Fund. For more information, please visit www.pervasistx.com.  

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products.

(1)  Dixon et al. DAC Study Group. Effect of dipyridamole plus aspirin on he
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
2. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
5. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
6. Mylan Receives Approval for Generic Version of Neurontin® Capsules
7. Elektas Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification
8. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
9. Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
10. Delcath Systems Receives Refusal to File Letter From FDA
11. Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Inc. (NASDAQ: UPI ), a medical device company ... treat voiding dysfunctions, today reported financial results for the ... Global revenue for the Company,s Urgent ®  PC Neuromodulation ... revenue record, as compared to $3.9 million in the ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
(Date:1/22/2015)... (NASDAQ: TECH ) announced today that it ... Simple Plex platform through its Proteins Platform division under ... the previously acquired CyPlex instrument platform from CyVek. ... technology which integrates an innovatively designed microfluidic cartridge with ...
Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... SAN DIEGO, March 21, 2011 Marshall Edwards, Inc.(Nasdaq: ... the clinical development of novel therapeutics targeting cancer metabolism, ... II clinical trial of intravenous Phenoxodiol in combination with ... is now available on the International Journal of ...
... 2011 CCS Medical today announced that its Board of ... for CCS Medical effective immediately.  Mr. Allison has been the ... "I am very excited about joining CCS Medical as its ... ourselves well in our markets and I look forward to ...
Cached Medicine Technology:Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol 2Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol 3
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
(Date:1/22/2015)... 2015 IsoComforter, Inc. has introduced the most ... IsoTube design to treat specific body parts and muscle groups. ... and easy to use patented cold therapy machine with the ... orthopedic and muscle injuries. IsoComforter has become the industry ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... found that the chance of successfully quitting can be ... their stay, and then have at least one month ... in to hospital provides an opportunity to stop smoking. ... has to stop temporarily while in hospital. People who ...
... What's billed as the world's biggest condom - a huge ... above a Dutch festival to increase safe sex awareness . ... Guinness Book of records - was commissioned by seven local ... Cross Festival in Lichtenvoorde, a small town near Almelo in ...
... the level of birth registration in certain parts of India ... year, 10 million still go unregistered . ,Two out ... not exist for government planning purposes, Plan India, a non-governmental ... deaths was made compulsory under the Registration of Births & ...
... people are unwilling or unable to stop smoking, but are ... smoke each day . ,After studying healthcare literature, ... reports that assessed methods aimed at helping people reduce use. ... cigarettes delivers clear health benefits. ,The main effort in ...
... death when seated, and not only when they are lying down, ... Childhood , a British journal. ,The findings are based ... among infants up to the age of 12 months in Quebec, ... deaths, 17, or 3.3 percent, occurred in babies who had been ...
... of extremes, boasts of almost a thousand no-sex-till-marriage organizations. ... Its brand ambassador beautiful teen Jami Waite, has been ... has risen from a single operation in Longview, Texas, ... can be abstinent, and its not weird, Waite declares. ...
Cached Medicine News:Health News:Hospital Provides an Oppurtunity to Quit Smoking 2Health News:Millions of Births Still Go Unreported in India 2Health News:Reducing Smoking - Mixed Messages and Latest Findings 2Health News:Virginity Rules-Meant To Be Broken? 2Health News:Virginity Rules-Meant To Be Broken? 3
... offers all of the benefits and ... with the additional feature of being ... imaging scanner for importing and storage ... or images. This additional feature allows ...
Inquire...
... Normal and Hypergamma Controls are ... either agarose gels or Sebia's ... Our unique control manufacturing process ... the other serum components, presenting ...
... Sebia's semi-automated agarose gel electrophoresis ... many tedious steps involved in classic ... system carries out all phases of ... migration to incubation to staining, destaining ...
Medicine Products: